<DOC>
	<DOCNO>NCT02684812</DOCNO>
	<brief_summary>This multicenter , prospective , randomize , open-label trial blind endpoint ( PROBE ) assessment . Adult patient diagnosis non-traumatic SAH , proven compute tomography ( CT ) within 24 hour onset headache , randomly assign treatment group control group . Patients treatment group receive standard treatment addition bolus TXA ( 1 g intravenously ) immediately randomization , follow continuous infusion 1 g per 8 hour start aneurysm treatment , maximum 24 hour start medication . Patients control group receive standard treatment without TXA . The primary outcome measure favorable functional outcome , define score 0 3 modified Rankin Scale ( mRS ) , 6 month SAH . Primary outcome determine trial nurse blind treatment allocation .</brief_summary>
	<brief_title>Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage .</brief_title>
	<detailed_description>Approximately 50 % patient subarachnoid hemorrhage ( SAH ) die due hemorrhage subsequent complication . There several major cause course , in-hospital rebleed 21.5 % frequently occur within first 6 hour primary hemorrhage ( `` ultra-early rebleed '' ) . A major part patient rebleed die hospital admission survive , develop severe cognitive dysfunction . Reducing rebleeds ultra-early administration tranexamic acid ( TXA ) could major factor improve functional outcome SAH . To evaluate whether SAH patient treat state-of-the-art SAH management additional ultra-early short term TXA administration significantly high percentage favourable outcome six month ( score 0-3 Modified Rankin Scale ) compare group treat up-to-date SAH management without additional TXA . To evaluate whether : 1 ) TXA reduce in-hospital rebleeds case fatality ; 2 ) TXA cause ischemic stroke 3 ) TXA cause complication ( thromboembolic event , hydrocephalus , extracranial thrombosis hemorrhagic complication ) treatment , admission follow-up ; 4 ) difference cause poor outcome group ; 5 ) difference discharge location group ; 6 ) association time hemorrhage TXA administration outcome ; 7 ) TXA increase ( micro ) infarction endovascular treatment ; 8 ) TXA reduce health-care cost discharge six month hemorrhage ; 9 ) TXA improve quality life six month hemorrhage ; 10 ) difference rebleed rate outcome gender group different WFNS score admission . Multicenter , prospective , randomize , open label treatment blind endpoint assessment . Adult patient ( 18 year old ) include within 24 hour SAH . Group one : standard treatment additional administration 1 g TXA intravenously ten minute , immediately diagnosis SAH , succeed continuous infusion 1 g per 8 hour maximum 24 hour . Group two : standard treatment TXA administration . Both group undergo standardize validated interview discharge six month hemorrhage assess modify Rankin Scale score , group receive questionnaire evaluate health-care cost quality life . Primary : modify Rankin Scale score six month , dichotomize favourable unfavourable outcome . Secondary : rebleed case fatality rate , complication first six month hemorrhage , ( micro ) infarction MR image endovascular treatment , health-care cost discharge six month , quality life six month difference rebleed rate outcome gender WFNS score admission . Nature extent burden risk associate participation , benefit group relatedness : Subjects randomly allocate ultra-early TXA therapy standard treatment . Complications minor expect benefit large compare separate study do antifibrinolytic medication . In study , safety use medication study population confirm . In patient group adequate , disorient comatose patient admission , part study patient incapacitated undergoing study . To extrapolate conclusion study clinical protocol necessary include patient SAH different severity grade . Weighing carefully benefit versus burden risk , assume patient benefit ultra-early TXA administration minimal burden therapy .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Admission one study center refer hospital CTconfirmed SAH recent ictus le 24 hour ago Definition : subarachnoid hemorrhage bleed pattern compute tomography hyperdensity basal cisterns and/or Sylvian interhemipheric fissure intraparenchymal hyperdensity consistent hematoma anterior , pericallosal , posterior middle cerebral artery aneurysm . No proficiency Dutch English language No loss consciousness hemorrhage WFNS grade 1 2 admission combination perimesencephalic hemorrhage Definition : CT examination presence hyperdensities exclusively basal cistern maximal extend proximal part Sylvian fissure posterior part interhemispheric fissure , without evidence intracerebral intraventricular haemorrhage ( except slight sedimentation ) Bleeding pattern CT compatible traumatic SAH Treatment deep vein thrombosis pulmonary embolism History blood coagulation disorder ( hypercoagulability disorder ) Pregnancy check pregnancy test woman childbearing period History severe renal ( serum creatinin &gt; 150 mmol/L ) History severe liver failure ( AST &gt; 150 U/l ALT &gt; 150 U/l AF &gt; 150 U/l Î³GT &gt; 150 U/l ) Imminent death within 24 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>antifibrinolytic therapy</keyword>
	<keyword>recurrent bleeding</keyword>
	<keyword>tranexamic acid</keyword>
</DOC>